Fed’s Powell opens door to potential rate cuts at Jackson Hole
Tuesday, Select Medical (NYSE:SEM) Holdings Corporation (NYSE:SEM) shares saw its price target increased by Benchmark to $48.00, up from the previous target of $42.00, while the firm retained a Buy rating on the stock.
The adjustment comes in the wake of Select Medical's announcement regarding the initial public offering (IPO) of Concentra. The IPO involves 22.5 million shares being offered within a price range of $23 to $26.
Select Medical disclosed that following the IPO, it would retain ownership of 104.1 million shares, equating to 82.2% of the total outstanding shares of Concentra, or 80.1% if the over-allotment option of 3.375 million shares is exercised.
Benchmark's analysis, which considers Concentra's standalone valuation, suggests that the anticipated price range corresponds to an enterprise value to EBITDA (EV/EBITDA) multiple of 11 to 12 times for the fiscal year 2025.
The analyst's statement highlighted that the new price target for Select Medical is based on the lower end of Concentra's proposed IPO price range. This assessment aligns with Benchmark's previous sum-of-the-parts (SOTP) valuation for Select Medical, which estimated a valuation of approximately $50. The increase in the price target to $48 reflects a positive outlook on the IPO's impact on Select Medical's market valuation.
In other recent news, Select Medical Holdings Corporation's subsidiary, Concentra Group Holdings Parent, Inc., is preparing for its initial public offering (IPO) with a price range set between $23.00 to $26.00 per share.
Concentra aims to list on the New York Stock Exchange, with the final IPO size and terms dependent on market conditions and other factors. Select Medical will retain a majority stake in Concentra post-IPO.
In parallel, Concentra has launched a $750 million senior notes offering, a move that is part of a broader plan to separate Concentra from Select Medical. The proceeds will be used for corporate expenses and to pay a dividend to Select Medical Corporation.
Select Medical has reported a strong first quarter, with a 22% increase in adjusted EBITDA and a 7% rise in revenue year-over-year. The company's Critical Illness Recovery hospitals experienced significant growth, contributing to its overall robust performance.
Analysts at Benchmark and RBC Capital have positively assessed the company's performance, leading to raised price targets. Benchmark increased its target to $42, while RBC Capital raised its target to $40, both maintaining their respective Buy and Outperform ratings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.